Evidence map›Paper›PMID 35058349›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2022

Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis.

Daniel Tusé, Micaela Reeves, Joshua Royal, Krystal T Hamorsky, Hanna Ng, Maria Arolfo, Carol Green, Abhishek Trigunaite, Toufan Parman, Goo Lee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniel TuséGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Micaela ReevesGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Joshua RoyalGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Krystal T HamorskyGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Hanna NgGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Maria ArolfoGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Carol GreenGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Abhishek TrigunaiteGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Toufan ParmanGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Goo LeeGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.).
Nobuyuki MatobaGROW Biomedicine, LLC and DT/Consulting Group, Sacramento, California (D.T.); Department of Pharmacology and Toxicology (M.R., J.R., N.M.), Department of Medicine (K.T.H.), and James Graham Brown Cancer Center, Center for Predictive Medicine (K.T.H., N.M.), University of Louisville, Louisville, Kentucky; SRI Biosciences Division, SRI International, Menlo Park, California (H.N., M.A., C.G., A.T., T.P.); and Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (G.L.) n.matoba@louisville.edu.

Funding

Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapyR01DK123712 · NIDDK · UNIVERSITY OF LOUISVILLE · PI MATOBA, NOBUYUKI · 2020 to 2023
$1.8M
NIDDK NIH HHS R01 DK123712
6 · The paper itself

Abstract

The novel wound-healing biologic EPICERTIN, a recombinant analog of cholera toxin B subunit, is in early development for the management of ulcerative colitis. This study established for the first time the pharmacokinetics (PK), bioavailability (BA), and acute safety of EPICERTIN in healthy and dextran sodium sulfate-induced colitic mice and healthy rats. For PK and BA assessments, single administrations of various concentrations of EPICERTIN were given intravenously or intrarectally to healthy and colitic C57BL/6 mice and to healthy Sprague-Dawley rats. After intravenous administration to healthy animals, the drug's plasma half-life (

Indexed as

Biological ProductsColitis, UlcerativeWound HealingAdministration, TopicalAnimalsDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLRatsRats, Sprague-DawleyRodentiaBiological Products

Identifiers

PMID35058349
PMCPMC11046972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.